NCT05835687View on ClinicalTrials.gov

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Central Nervous System NeoplasmsAtypical Teratoid/Rhabdoid TumorDiffuse Midline Glioma, H3 K27M-MutantEpendymomaHigh Grade GliomaGlioblastomaMedulloblastoma
Interventions
DRUG

B7-H3-CAR T cells

Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Four (4) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.

Trial Locations (1)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER